In its response, Pfizer said that alternative dosing regimens of its vaccine had not been evaluated yet and the decision to do that resided with the health authorities. “We at Pfizer believe that it is critical for health authorities to conduct surveillance on implemented alternative dosing schedules to ensure that vaccines provide the maximum possible protection,” the company added.
